作者
Richard S Legro, Robert G Brzyski, Michael P Diamond, Christos Coutifaris, William D Schlaff, Peter Casson, Gregory M Christman, Hao Huang, Qingshang Yan, Ruben Alvero, Daniel J Haisenleder, Kurt T Barnhart, G Wright Bates, Rebecca Usadi, Scott Lucidi, Valerie Baker, JC Trussell, Stephen A Krawetz, Peter Snyder, Dana Ohl, Nanette Santoro, Esther Eisenberg, Heping Zhang
发表日期
2014/7/10
期刊
New England Journal of Medicine
卷号
371
期号
2
页码范围
119-129
出版商
Massachusetts Medical Society
简介
Background
Clomiphene is the current first-line infertility treatment in women with the polycystic ovary syndrome, but aromatase inhibitors, including letrozole, might result in better pregnancy outcomes.
Methods
In this double-blind, multicenter trial, we randomly assigned 750 women, in a 1:1 ratio, to receive letrozole or clomiphene for up to five treatment cycles, with visits to determine ovulation and pregnancy, followed by tracking of pregnancies. The polycystic ovary syndrome was defined according to modified Rotterdam criteria (anovulation with either hyperandrogenism or polycystic ovaries). Participants were 18 to 40 years of age, had at least one patent fallopian tube and a normal uterine cavity, and had a male partner with a sperm concentration of at least 14 million per milliliter; the women and their partners agreed to have regular intercourse with the intent of conception during the study. The primary …
学术搜索中的文章
RS Legro, RG Brzyski, MP Diamond, C Coutifaris… - New England Journal of Medicine, 2014